Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
TaiMed Biologics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 0.57%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for TaiMed Biologics's 3-Year ROIIC % or its related term are showing as below:
ROCO:4147's 3-Year ROIIC % is ranked better than 53.53% of 1319
companies
in the Biotechnology industry
Industry Median: -4.85
vs ROCO:4147: 0.57
TaiMed Biologics (ROCO:4147) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
TaiMed Biologics 3-Year ROIIC % Related Terms
TaiMed Biologics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for TaiMed Biologics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4147 vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, TaiMed Biologics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiMed Biologics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiMed Biologics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where TaiMed Biologics's 3-Year ROIIC % falls into.
TaiMed Biologics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -194.646 (Dec. 2025) - -191.856 (Dec. 2022) )
/
( 2959.01 (Dec. 2025) - 3451.288 (Dec. 2022) )
=
-2.79
/
-492.278
=
0.57%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
TaiMed Biologics (ROCO:4147) has a 3-Year ROIIC % of 0.57 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TaiMed Biologics and its competitors. According to the industry distribution chart, TaiMed Biologics ranks #613 out of 1319 companies in the Biotechnology industry, placing it in the top 46.5%.
Is TaiMed Biologics' 3-Year ROIIC % too high?
TaiMed Biologics' current 3-Year ROIIC % is 0.57. Based on the distribution chart, TaiMed Biologics ranks #613 out of 1319 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TaiMed Biologics has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #613 out of 1319 companies for 3-Year ROIIC %. This puts TaiMed Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on TaiMed Biologics and its competitors. TaiMed Biologics's current 3-Year ROIIC % is 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$83.20, compared to a current price of NT$58.00 — trading 30.3% below its estimated fair value. The current 3-Year ROIIC % is 0.57. TaiMed Biologics' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current 3-Year ROIIC % is 0.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?
Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued.
The current stock price of NT$58.00 is trading 30.3% below its estimated GF Value™ of NT$83.20.
GuruFocus considers TaiMed Biologics to be Significantly Undervalued.
Key valuation signals for ROCO:4147:
3-Year ROIIC %: 0.57
GF Value™: NT$83.20 vs. price of NT$58.00 (30.3% below fair value)
No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
59GF Score
Get the complete analysis for ROCO:4147
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4147 has been successfully added to your 
